Boehringer's survodutide hits Phase III endpoints in obesity plus T2D
Boehringer Ingelheim has reported positive Phase III results from its SYNCHRONIZE-2 trial, in which the glucagon/GLP-1 receptor dual agonist survodutide produced statistically significant weight loss and glycaemic improvements in adults living with obesity or overweight and type 2 diabetes (T2D). The trial met both co-primary endpoints, and full results were presented on 1 October at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and published simultaneously in the New England Journal of Medicine.
In the 76-week, double-blind, placebo-controlled study of 755 participants, those treated with survodutide achieved average body weight reductions of up to 13.1% using the efficacy estimand, compared with 3.1% in the placebo group. Up to 79.3% of participants on survodutide achieved at least a 5% reduction in body weight, versus 32.7% on placebo. Both comparisons reached statistical significance (p<0.0001). The result is notable given that patients with T2D typically achieve less pronounced weight loss from anti-obesity therapies than those without the condition.
Cardiometabolic benefits beyond the scale
Key secondary endpoints reinforced the metabolic breadth of the drug's activity. HbA1c fell by up to 1.21 percentage points from a baseline of 7.4%, against a 0.03-point reduction in the placebo arm, and waist circumference shrank by 11.1 cm versus 3.5 cm on placebo. Markers of insulin sensitivity also improved, including favourable changes in HOMA-IR and fasting plasma glucose. Up to 29.5% of survodutide-treated participants reverted to normoglycaemia (HbA1c below 5.7%), compared with 4.0% on placebo.
Separately presented data from a body composition sub-study of SYNCHRONIZE-1 (the non-T2D arm of the programme) used MRI to show preferential reductions in visceral and liver fat, with muscle accounting for no more than 10% of total tissue lost. Boehringer said these findings suggest fat-targeting effects that may operate independently of overall weight loss.
Coordinating investigator Dr Sean Wharton said the data offer "new optimism to people seeking more effective ways to improve their overall health," adding that the simultaneous improvements in glycaemic control and insulin sensitivity support a view of obesity as a systemic metabolic disorder rather than simply a weight problem.
Gastrointestinal adverse events were the most common safety finding, consistent with the class profile of GLP-1-based therapies. Nausea, vomiting, diarrhoea and constipation were reported most frequently; 18% of survodutide-treated patients discontinued due to GI events, compared with 1.2% in the placebo group. Boehringer noted that discontinuations were concentrated in the dose-escalation phase and said upcoming trials will allow more flexible patient-centred titration to improve tolerability.
Competitive landscape and what comes next
The cardiometabolic obesity market is one of the most actively contested in the pharmaceutical industry. Novo Nordisk's semaglutide (Wegovy/Ozempic) and Eli Lilly's tirzepatide (Mounjaro/Zepbound) have set high bars for both weight loss and metabolic benefit in large outcomes programmes. Survodutide's dual glucagon/GLP-1 mechanism is differentiated from pure GLP-1 agonists on paper, but investors and clinicians will want to see head-to-head data and, critically, cardiovascular outcomes results before drawing firm conclusions about its positioning.
Boehringer expects to present data from the SYNCHRONIZE-CVOT cardiovascular outcomes trial before the end of 2026, a readout that could prove pivotal for the drug's commercial profile. The company has also launched SYNCHRONIZE-T2D, a further Phase III study examining glycaemic control in adults managing T2D with diet, exercise, or existing diabetes medications including insulin. In the liver disease space, survodutide holds FDA Breakthrough Therapy designation for MASH and fibrosis, with two Phase III LIVERAGE trials ongoing. Survodutide is licensed to Boehringer from Zealand Pharma, with Boehringer holding sole responsibility for global development and commercialisation.